Condensed Consolidated Statements of Loss and Comprehensive Loss - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Revenue
Research and development collaborations (note 9)	$ 12,359	$ 7,882	$ 20,628	$ 19,807
Operating expenses:
Research and development	39,217	23,785	75,743	41,260
General and administrative	13,491	12,761	21,114	21,764
Impairment on acquired IPR&D	0	768	0	768
Total operating expenses	52,708	37,314	96,857	63,792
Loss from operations	(40,349)	(29,432)	(76,229)	(43,985)
Other income (expense):
Interest income	1,502	1,233	3,358	2,482
Other (expenses) income, net (note 10)	(178)	(243)	3,085	(387)
Total other income, net	1,324	990	6,443	2,095
Loss before income taxes	(39,025)	(28,442)	(69,786)	(41,890)
Income tax recovery (expense)	64	(635)	(311)	(828)
Net loss and comprehensive loss	$ (38,961)	$ (29,077)	$ (70,097)	$ (42,718)
Net loss per common share (note 4):
Basic and diluted (in dollars per share)	$ (0.77)	$ (0.89)	$ (1.41)	$ (1.32)
Weighted-average common shares outstanding (note 4):
Basic and diluted (in shares)	50,788,681	32,837,975	49,737,699	32,431,464